SG
LIMN

StoneX Group’s Liminatus Pharma LIMN Stock Holding History

StoneX Group’s Portfolio LIMN Stock Details LIMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.93K Buy
+26,058
New +$4.5K ﹤0.01% 1427

Other funds holding LIMN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $12.2B AUM 47.93% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

StoneX Group's LIMN Position: Q2 2026 in Review

StoneX Group opened a new position in Liminatus Pharma (LIMN) in Q2 2026: 26,058 shares worth $3.93K. The stake represents ﹤0.01% of the portfolio and ranks #1427 among its holdings.

9 funds tracked by Wall St. Rank hold LIMN as of Q2 2026.

  • StoneX Group held 26,058 shares of Liminatus Pharma worth $3.93K as of Q2 2026.
  • Liminatus Pharma was a new StoneX Group position in Q2 2026.
  • Liminatus Pharma made up ﹤0.01% of StoneX Group's portfolio in Q2 2026, its #1427 holding.
  • 9 funds tracked by Wall St. Rank held Liminatus Pharma as of Q2 2026.

Based on StoneX Group's 13F filing for Q2 2026, filed 12 Aug 2026.